Key Highlights
- OSSIO raises $27.6M in equity funding led by Questa Capital to scale operations.
- Focus on new product pipeline, U.S. manufacturing, and surgeon training center in Florida.
- Over 50,000 OSSIOfiber implants used since 2019 across diverse orthopedic procedures.
- OSSIOfiber implants fully integrate with bone, offering a credible alternative to metal.
- Expansion to strengthen U.S. and international sales channels and support surgeon adoption.
Source: Business Wire
Notable Quotes
- “This new investment in OSSIO strengthens our ability to build upon our proven claim as the most innovative and differentiated implant technology to enter the $16 billion orthopedic fixation market.” – Brian Verrier, CEO at OSSIO
- “OSSIO fits squarely into our investment strategy. The company is growing rapidly and has established OSSIOfiber implants as a differentiated and disruptive medical technology with clear patient benefits and passionate surgeon users.” – Ryan Drant, Founder and Managing Partner at Questa Capital
SoHC's Take
OSSIO’s latest funding milestone demonstrates the market’s confidence in bio-integrative technologies as a superior alternative to traditional metal implants. With OSSIOfiber implants addressing critical needs in orthopedic fixation—such as eliminating post-surgical complications linked to permanent materials—OSSIO is well-positioned to reshape orthopedic surgery. Their strategic expansion in U.S. manufacturing and surgeon training will likely accelerate adoption and further their mission to redefine patient care. This innovation not only aligns with healthcare trends favoring sustainable, patient-centric solutions but also establishes OSSIO as a transformative leader in the $16 billion orthopedic fixation market.
